Evidence map›Paper›PMID 37127264›Full record

ArticleThe American journal of tropical medicine and hygiene2023

Investigation of Four Cases of Stevens-Johnson Syndrome among Participants in a Mass Drug Administration Campaign with Sulfadoxine-Pyrimethamine and Primaquine in Haiti, 2020.

Michelle A Chang, Bernadette Fouché, Willy LaFortune, Kathleen Holmes, Jonas Rigodon, Stanley Juin, Samson Marseille, Eric Rogier, Michael Green, Taba Kheradmand and 4 more

Open access · hybridAbstract read
In one paragraph

Article in The American journal of tropical medicine and hygiene, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Michelle A ChangMalaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.
Bernadette FouchéCDC Foundation, Atlanta, Georgia.
Willy LaFortuneProgramme National de Contrôle de la Malaria, Ministère de la Santé Publique et de la Population, Port-au-Prince, Haiti.
Kathleen HolmesMalaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.
Jonas RigodonCDC-Haiti, Division of Global Health Protection, Center for Global Health, Centers for Disease Control and Prevention, Port-au-Prince, Haiti.
Stanley JuinCDC-Haiti, Division of Global Health Protection, Center for Global Health, Centers for Disease Control and Prevention, Port-au-Prince, Haiti.
Samson MarseilleLaboratoire National de la Santé Publique, Ministère de la Santé Publique et de la Population, Port-au-Prince, Haiti.
Eric RogierMalaria Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.
Michael GreenEntomology Branch, Division of Parasitic Diseases and Malaria, Center for Global Health, Centers for Disease Control and Prevention, Atlanta, Georgia.
Taba KheradmandFred H. Allen Immunogenetics Laboratory, New York Blood Center, New York, New York.
Samuel G MooreParker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, Georgia.
David A GaulParker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, Atlanta, Georgia.
Jacques BoncyLaboratoire National de la Santé Publique, Ministère de la Santé Publique et de la Population, Port-au-Prince, Haiti.
Marc-Aurele TelfortProgramme National de Contrôle de la Malaria, Ministère de la Santé Publique et de la Population, Port-au-Prince, Haiti.
Center for Global Health · USGeorgia Institute of Technology · USCDC Foundation · USCenters for Disease Control and Prevention · USDivision of Parasitic Diseases and Malaria · USNew York Blood Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2018, a mass drug administration (MDA) campaign for malaria elimination was piloted in Haiti. The pilot treated 36,338 people with sulfadoxine-pyrimethamine (SP) and primaquine; no severe adverse events were detected. In 2020, another MDA campaign using the same medications was implemented to mitigate an upsurge in malaria cases during the COVID-19 pandemic. Four cases of Stevens-Johnson syndrome (SJS) were identified among the 42,249 people who took the medications. Three of these individuals required hospitalization; all survived. In addition to SP ingestion, an investigation of potential causes for increased SJS cases identified that all four cases had human leukocyte antigens A*29 and/or B*44:03, another known risk factor for SJS. Additionally, three of the four case individuals had antibodies to SARS-CoV-2, and the fourth may have been exposed around the same time. These findings raise the possibility that recent SARS-CoV-2 infection may have contributed to the increased risk for SJS associated with SP exposure during the 2020 campaign.

Indexed as

AntimalarialsCOVID-19MalariaStevens-Johnson SyndromeDrug CombinationsHaitiHumansMass Drug AdministrationPandemicsPrimaquinePyrimethamineSARS-CoV-2SulfadoxineAntimalarialsDrug Combinationsfanasil, pyrimethamine drug combinationPrimaquinePyrimethamineSulfadoxine

Identifiers

PMID37127264
PMCPMC10540108
OpenAlexW4367596251

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.